At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 20 enrolled
Drug / intervention
Apremilastdrug
Likely dose
Apremilast 30 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Open-label Pilot Study to Investigate the Efficacy of Apremilast in the Treatment of Central Centrifugal Cicatricial Alopecia (CCCA)
In Brief
A Phase 4 clinical trial evaluating Apremilast for Central Centrifugal Cicatricial Alopecia. Completed, enrolled 20 participants across 1 site.
Detailed Summary
This is a single-center, open-label clinical study to study the efficacy of apremilast in the treatment of mild to moderate central centrifugal cicatricial alopecia. The investigators hypothesize that the anti-inflammatory properties of apremilast may play a role in the decreasing scalp inflammation in patients with CCCA and may prevent further hair loss and potentially induce hair regrowth in patients with mild to moderate disease.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCentral Centrifugal Cicatricial Alopecia
CountriesUnited States
Collaborators--
Timeline
Phase 4CompletedFinished
20192020202120222023202420252026
First PostedMay 2018
Enrollment StartNov 2018
Primary CompletionFeb 2021
TodayJul 2026
First PostedMay 11, 2018
Enrollment StartNov 15, 2018
Primary CompletionFeb 12, 2021
TodayJul 2, 2026
Enrollment to primary: 2.2 yearsPosted 8.1 years ago
Interventions
Apremilastdrug
30 mg BID